BioWorld Asia

Aug. 14, 2002

Peptor's DiaPep277 Diabetes Product Licensed By Aventis

JERUSALEM, Israel - Peptor Ltd. said July 30 it signed a worldwide agreement with Aventis SA, granting it exclusive rights to develop and commercialize Peptor's DiaPep277 drug for the treatment of autoimmune diabetes. (BioWorld International) Read More

British Biotech Collaborates With GeneSoft In Anti-Infectives Deal

Cureon Raises DKK34M For Antisense DNA Analogue

Evolutec Raises £1.8 Million In Third Round Of Financing

Compugen Uploads Gencarta Database, Extends Pfizer Deal

Other News To Note

Phico Raises £450,000 To Begin Antibiotic Development

Start-Up NascaCell's Platform Speeding Drug Discovery

Pharmos To Study Dexanabinol In Impairment Following Surgery

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...